The computational studies support the hypothesis that Coniferin and Tetrahydrocurcumin can be potent inhibitors of PSAT1 in early-stage ovarian cancer, and both are natural compounds, relatively non-toxic, making them good candidates for further development as PSAT1 inhibitors. The gene discussed is PSAT1; the disease is ovarian cancer.